FT516 in Subjects With Advanced Hematologic Malignancies
Is a
Allocation Type
Non-Randomized
0
Participating Facility
Health Conditions in Trial
Intervention Model
Parallel Assignment
0
Intervention Name
IL-2
0
Fludarabine
0
Rituximab
0
Obinutuzumab
0
FT516
0
Cyclophosphamide
0
Bendamustine
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
October 26, 2023
0
Masking Type
None (Open Label)
0
Primary Completion Date
October 23, 2023
0
Trial Recruitment Size
72
0
Trial Sponsor
Clinical Trial Start Date
October 4, 2019
0
Study Completion Date
October 23, 2023
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
0
Official Website
Find more entities like FT516 in Subjects With Advanced Hematologic Malignancies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.